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Abstract
Purpose: To compare the long-term outcomes in patients with salivary gland adenoid cystic carcinoma (SGACC)
treated with post-operative chemoradiotherapy (POCRT) versus post-operative radiotherapy (PORT).
Methods: We retrospectively reviewed the records of 91 SGACC patients treated with surgery followed by PORT
(n = 58) or POCRT (n = 33) between 2000 and 2013. Treatment outcomes between groups were compared using
propensity score matching (1:1 nearest neighbor).
Results: The median radiation dose was 66 Gy, and patients were followed up for a median of 71 months.
Cisplatin-based concurrent regimens were the most commonly used chemotherapy schedules. In the entire study
cohort, patients undergoing POCRT showed a trend toward higher locoregional control (LRC) rates than those
treated with PORT alone at both 5 and 8 years (97 and 97 % versus 84 and 79 %, respectively; P = .066). Distant
metastases were the most common form of treatment failure and occurred in 31 (34 %) patients (PORT, n = 17;
POCRT, n = 14). After propensity score matching (33 pairs), patients receiving POCRT had 5- and 8 year LRC rates of
97 and 97 %, respectively, compared with 79 and 67 % for patients treated with PORT alone (P = .017). The two
groups did not differ significantly in terms of distant metastasis-free survival (DMFS), disease-free survival (DFS), and
overall survival (OS). However, a significantly better opioid-requiring pain-free survival (ORPFS) was achieved in
POCRT group (P = .038). Subgroup analyses revealed that patients with stage III − IV disease (P = .040 and .017),
positive surgical margins (P = .011 and .050), or perineural invasion (P = .013 and .035) had significantly higher
5- and 8 year LRC and ORPFS when treated with POCRT, respectively.
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Conclusions: In SGACC patients, adding concurrent chemotherapy to PORT may increase LRC and ORPFS rates,
particularly in presence of stage III − IV disease, positive surgical margins, or perineural invasion. However, no
significant differences in DMFS, DFS, and OS were observed.
Keywords: Salivary gland cancer, Chemoradiotherapy, Adenoid cystic carcinoma, Postoperative radiotherapy,
Propensity score, Head and neck
Introduction
Despite being the most common form of salivary gland
cancer, salivary gland adenoid cystic carcinoma (SGACC)
is a rare malignancy which accounts for only 1 % of all
head and neck tumors [1, 2]. Because of its local invasive-
ness, post-operative radiotherapy (PORT) is frequently
used to increase locoregional control (LRC), particularly
in patients bearing adverse prognostic factors, including
positive surgical margins, advanced T stage, and perineural
invasion (PNI) [3–5]. Despite important advances in com-
bination therapies, the 10 year rate of locoregional recur-
rence continues to remain high (~30 %) [3–5]. Several
multicenter randomized trials have demonstrated the ef-
fectiveness of post-operative chemoradiotherapy (POCRT)
in patients with head and neck squamous cell carcinoma
(HNSCC) [6–8]. However, as a result of the rarity of
SGACC, data concerning the role of adjuvant therapies in
this clinical entity remain scarce. Although chemotherapy
is generally reserved for the treatment of recurrent or
metastatic SGACC [9], the clinical usefulness of adding
concurrent chemotherapy to PORT remains unclear.
Based on the evidence supporting the clinical utility of
POCRT in HNSCC patients [6–8], we have been utiliz-
ing POCRT in our SGACC patients bearing adverse
prognostic factors. In the present study, we retrospect-
ively investigated the long-term outcomes of SGACC pa-
tients who were treated with surgery followed by PORT
or POCRT in our institutions. Treatment outcomes be-
tween the PORT and POCRT groups were compared
using propensity score matching in order to minimize
biases. We also performed subgroup analyses with the
goal of identifying specific SGACC patients who can
benefit most from POCRT.
Materials and method methods
Patients and clinical work-up
The study complied with the tenets of the Declaration of
Helsinki and the research protocol was approved by the
local Institutional Review Board (102-0938B). We retro-
spectively reviewed the records of 174 SGACC patients
who were treated in the Linkou, Keelung, and Chiayi
Chang Gung Memorial Hospitals between January 2000
and December 2013. After the exclusion of patients with
unresected tumors (N = 24), distant metastases (N = 23),
synchronous cancers (N = 4), a history of previous radio-
therapy (RT) in the head and neck area (N = 6), and no
adjuvant RT after surgery (N = 26), a total of 91 patients
who received either PORT or POCRT were included in
the final analysis.
The pretreatment work-up and the follow-up schedules
were in accordance with the general guidelines for HNSCC
patients as previously described [10]. Patient staging was
performed according to the seventh edition (2010) of the
American Joint Committee on Cancer (AJCC) Staging
System. All of the pathological specimens were reviewed
by experienced head and neck pathologists according
to the 2005 World Health Organization (WHO) histo-
logical classification. Treatment-related adverse events
were graded using the Common Terminology Criteria
for Adverse Events (CTCAE; version 3.0) [11].
Treatment
All of the treatment decisions were taken by consensus
of multidisciplinary Head and Neck Tumor Boards.
Neck dissection was performed in patients with clinically
positive nodes or locally advanced tumors. The study pa-
tients received surgical treatment with curative intent
followed by either PORT (N = 58) or POCRT (N = 33).
All of the patients received megavoltage X-ray irradia-
tions via three-dimensional conformal radiotherapy
(3D-CRT), intensity-modulated radiation therapy (IMRT),
or volumetric-modulated arc therapy (VMAT, RapidArc)
delivery systems. The prophylactic irradiation dose was
46–50 Gray (Gy), with a 60–66 Gy boost to high-risk areas
(dose per fraction: 1.8–2 Gy, given five times per week).
Over the last years, there was an increasing use of chemo-
radiotherapy in our patient population. In general, chemo-
therapy was administered in patients with advanced
disease or in presence of adverse pathological risk factors
[6, 7, 10]. Cisplatin-based concurrent regimens were the
most commonly used chemotherapy schedules. Patients
typically received cisplatin at 100 mg/m2 once every
3 weeks or 40 mg/m2 once per week [12].
Statistical analysis
Intergroup differences in continuous variables were
tested using independent Student’s t-tests. Categorical
data were compared using the Pearson’s chi-squared test
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or the Fisher’s exact test, as appropriate. LRC, distant
metastasis-free survival (DMFS), disease-free survival
(DFS), and overall survival (OS) were calculated from
the date of surgery to the date of the events of interest.
Opioid-requiring pain-free survival (ORPFS) was cal-
culated based on the date of the first prescription of
opioids for the relief of any pain occurring 6 months
after adjuvant therapy. Survival curves were plotted
using the Kaplan-Meier method and compared using
the log-rank test. The propensity score was estimated
using logistic regression, with the dependent variable
being treatment with POCRT. All data were analyzed
using the SPSS 20.0 software package (IBM Corpor-
ation, Armonk, NY, USA). Propensity score matching
was performed using the MatchIt package of the R




The general characteristics of the study patients are
summarized in Table 1. Patients who were treated with
POCRT were characterized by a significantly higher
prevalence of positive surgical margins (defined as any
resection margin width of less than 1 mm; P = .032) and
nodal extracapsular spread (ECS) (P = .022), a signifi-
cantly longer time interval between surgery and RT
(P = .018) and trends toward higher T stage (P = .099),
larger tumor size (P = .051) and higher bone invasion
rate (P = .066). Compared with patients who received
PORT, those treated with POCRT were also more
likely to receive magnetic resonance imaging (MRI)
(P = .044), 18F-fluorodeoxyglucose positron emission
tomography (18F-FDG-PET; P = .039), IMRT/VMAT
(P < .001), and having been treated with RT more re-
cently (2010–2013 versus 2005–2009 versus 2000–
2004; P = .001).
The median cumulative radiation dose for the entire
study cohort was 66.0 Gy (range: 7.2–76.0 Gy). Elective
neck treatments including neck dissection (N = 13) and/or
irradiation (N = 41) were applied to 42 patients. We found
no statistically significant differences in terms of radiation
dose, neck treatment modality, and duration of radiother-
apy between the PORT and POCRT groups (Table 1).
Intravenous cisplatin-based concurrent chemotherapy
was administered to 31 (94 %) of the 33 POCRT patients.
Among them, a single agent was given to 22 patients,
whereas concurrent oral uracil-tegafur and cisplatin were
used in nine patients. The median cumulative cisplatin
dose was 200 mg/m2. Twenty-four (77 %) of the 31 pa-
tients completed their planned chemotherapy course.
Non-cisplatin-based regimens consisted of either single-
agent mitomycin C (N = 1) or cetuximab (N = 1). Neither
neoadjuvant nor adjuvant chemotherapy were performed,
the only exception being seven patients who received one
or two courses of chemotherapy during the radiotherapy
waiting time.
Treatment outcomes
At the end of the study, 65 (71 %) patients were alive
(median follow-up time for survivors: 71 months; range:
8–186 months). Disease-specific deaths occurred in 20
patients (PORT, N = 14; POCRT, N = 6), and 19 of them
expired because of distant metastases. Only one patient
in the PORT arm died of local tumor progression. Death
caused by intercurrent diseases occurred in 6 study par-
ticipants (PORT, N = 4; POCRT, N = 2). The 5- and 8 year
OS rates in the entire cohort were 83 and 71 %, respect-
ively. In addition, ten (11 %) patients developed secondary
malignancies (PORT, n = 7; POCRT, n = 3), including
gastric (n = 3), pancreatic (n = 1), rectal (n = 1), ovarian
(n = 1), and pulmonary (n = 1) adenocarcinomas, gastro-
intestinal stromal tumor (n = 1), cholangiocarcinoma
(n = 1), and cervical squamous cell carcinoma (n = 1).
Recurrences were observed in 32 (35 %) patients, and
the 5- and 8 year DFS rates were 64 and 56 %, respect-
ively. Distant metastases were the most common form
of treatment failure and occurred in 31 (34 %) patients
after a median time of 34 months (range: 5–128). The 5-
and 8 year DMFS rates were 65 and 59 %, respectively.
Eleven (12 %) patients showed locoregional relapse
(median time: 27 months, range: 5–72 months), and
eight of them were found to occur within high radiation
dose regions. The detailed characteristics of patients who
developed locoregional recurrences are summarized in
Table 2. The 5- and 8 year cumulative LRC rates were 89
and 85 %, respectively.
Fourteen of the 32 patients with cancer recurrence
received salvage treatment (surgery, N = 6; radiotherapy,
N = 6; chemotherapy, N = 6), but none of them was suc-
cessfully rescued. The best supportive care was provided
to the remaining patients. However, several years of life
expectancy were observed in patients after a diagnosis of
cancer relapse. The median survival time was 29 months
(range: 7–108 months) for patients with locoregional
recurrence and 25 months (range: 1–98 months) for
cases with distant metastases, respectively. Twelve pa-
tients suffered from cancer-related pain requiring con-
tinuous long-term opioid analgesics. The 5- and 8 year
ORPFS rates were 91 and 83 % for the entire cohort, re-
spectively. In addition, the majority of patients with
locoregional failures experienced moderate-to-severe
symptoms, including cosmetic disfiguration (N = 9),
chronic ulceration (N = 6), soft tissue infections requir-
ing antibiotic treatment and hospitalization (N = 6),
numbness, paresthesia, or cranial nerve palsy (N = 9),
opioid-requiring pain (N = 8), and anxiety or insomnia
requiring drug therapy (N = 7).
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Table 1 General characteristics of the study patients
Entire Cohort Propensity Score Matching
Characteristic PORT (N = 58) POCRT (N = 33) P PORT (N = 33) POCRT (N = 33) P
Age (years) Mean 50 ± 15 51 ± 12 .793 48 ± 15 51 ± 12 .372
Sex Female/Male 37 (64)/21 (36) 17 (52)/16 (49) .275 18 (55)/15 (46) 17 (52)/16 (49) 1.000
Tumor subsite Parotid 16 (28) 6 (18) .394 7 (21) 6 (18) .692a
Submandibular 16 (28) 8 (24) 11 (33) 8 (24)
Sublingual 8 (14) 3 (9) 4 (12) 3 (9)
Minor salivary 18 (31) 16 (49) 11 (33) 16 (49)
Performance score 0-1/2 57 (98)/1 (2) 30 (91)/3 (9) .134a 33 (100)/0 (0) 30 (91)/3 (9) .238a
T stage T1 23 (40) 5 (15) .099 12 (36) 5 (15) .137a
T2 15 (26) 10 (30) 9 (27) 10 (30)
T3 5 (9) 5 (15) 1 (3) 5 (15)
T4 15 (26) 13 (39) 11 (33) 13 (39)
Tumor size (cm) Mean 2.4 ± 1.3 3.1 ± 1.7 .051 2.4 ± 1.3 3.1 ± 1.7 .060
N stage N0 52 (90) 26 (79) .332a 31 (94) 26 (79) .228a
N1 3 (5) 3 (9) 1 (3) 3 (9)
N2 3 (5) 4 (12) 1 (3) 4 (12)
Disease stage I 21 (36) 4 (12) .103 11 (33) 4 (12) .200a
II 14 (24) 10 (30) 8 (24) 10 (30)
III 6 (10) 5 (15) 2 (6) 5 (15)
IV 17 (29) 14 (42) 12 (36) 14 (42)
MRI 17 (29) 17 (52) .044 10 (30) 17 (52) .132
18F-FDG-PET 15 (26) 16 (49) .039 15 (46) 16 (49) 1.000
Surgical margins <1 mm/≥1 mm 38 (66)/20 (35) 28 (85)/5 (15) .032 26 (79)/7 (21) 28 (85)/5 (15) .751
Histological features Perineural invasion 38 (66) 27 (82) .147 24 (73) 27 (82) .558
Nodal ECS 1 (2) 5 (15) .022a 0 (0) 5 (15) .053a
Bone invasion 9 (16) 11 (33) .066 8 (24) 11 (33) .587
Skin invasion 2 (3) 0 (0) .533a 1 (3) 0 (0) 1.000a
Muscle invasion 19 (33) 7 (21) .335 11 (33) 7 (21) .408
Lymphatic invasion 5 (9) 4 (12) .718a 1 (3) 4 (12) .355a
Vascular invasion 2 (3) 3 (9) .349a 2 (6) 3 (9) 1.000a
RT technique 3D-CRT 30 (52) 3 (9) < .001 8 (24) 3 (9) .340
IMRT 19 (33) 20 (61) 17 (52) 20 (61)
VMAT 9 (16) 10 (30) 8 (24) 10 (30)
RT dose >66 Gy 13 (22) 6 (18) .678a 5 (15) 6 (18) .810a
60–66 Gy 41 (71) 26 (79) 25 (76) 26 (79)
<60 Gy 4 (7) 1 (3) 3 (9) 1 (3)
RT period 2010–2013 13 (22) 12 (36) .001 11 (33) 12 (36) .556
2005–2009 15 (26) 17 (52) 11 (33) 17 (52)
2000–2004 30 (52) 4 (12) 11 (33) 4 (12)
Neck treatment Elective 27 (47) 15 (46) .677 13 (39) 15 (46) .411
Therapeutic 8 (14) 7 (21) 4 (12) 7 (21)
None 23 (40) 11 (33) 16 (49) 11 (33)
Treatment time Surgery to RT (days) 31 ± 12 37 ± 11 .018 35 ± 11 37 ± 11 .544
RT duration (days) 47 ± 9 48 ± 4 .770 46 ± 6 48 ± 4 .189
Numbers in parentheses indicate percentages. Abbreviations: RT radiotherapy, PORT postoperative radiotherapy, POCRT postoperative chemoradiotherapy,
MRI magnetic resonance imaging, 18F-FDG PET 18F-Fluorodeoxyglucose positron emission tomography, ECS extracapsular spread, 3D-CRT 3-dimensional conformal
radiotherapy, IMRT intensity-modulated radiotherapy, VMAT RapidArc volumetric-modulated arc therapy. aFisher’s exact test
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Comparisons of POCRT and PORT
In the entire study cohort, a trend toward higher LRC
was identified in patients who received POCRT than
those who were treated with PORT alone at both 5 and
8 years (97 and 97 % versus 84 and 79 %, respectively;
P = .066, Fig. 1a). We also noted a trend toward better
5- and 8 year ORPFS rates in POCRT patients than in
the PORT group (96 and 96 % versus 88 and 78 %,
P = .084, Fig. 2a). However, no statistically significant
differences were observed between the two groups in
terms of DMFS, DFS, and OS (Fig. 1a).
To minimize the inherent selection biases in our retro-
spective cohort, we used propensity score matching to
balance the PORT and POCRT groups. To this aim, we fo-
cused on preexisting significant differences at the P ≤ 0.1
level (Table 1). We observed that higher disease
stages were significantly correlated with higher T
stages (P < .001), larger tumor size (P < .001), presence
of nodal ECS (P = .008), bone invasion (P < .001), and use
of MRI (P < .001). Moreover, patients who received mod-
ern RT techniques were more likely to be treated in recent
RT periods (P < .001) and receive 18F-FDG-PET (P < .001).
Therefore, we selected disease stage, RT technique, mar-
gin status, and interval from surgery to RT as independent
variables for propensity score calculation. Patients were
matched in a 1:1 ratio using the nearest-neighbor method,
without replacement. Finally, a total of 33 patient pairs
were examined to estimate the potential usefulness of
adding concurrent chemotherapy to PORT.
After propensity score matching, all of the preexisting
statistical differences between groups were well-balanced,
the only exceptions being trends toward a larger tumor
size (P = .060) and a higher prevalence of nodal ECS
(P = .053) in the POCRT group (Table 1). The median
follow-up period was 70 months for patients who
received POCRT and 68 months for patients treated with
PORT. Patients who were treated with POCRT had 5- and
8 year LRC rates of 97 and 97 %, respectively, compared
with 79 and 67 % for patients who received PORT alone
(P = .017, Fig. 1b). No significant differences between the
POCRT and PORT groups were observed in terms of
DMFS, DFS, and OS (Fig. 1b). However, significantly bet-
ter 5- and 8 year ORPFS rates were achieved in POCRT
patients than in the PORT group (96 and 96 % vs 82 and
71 %, P = .038, Fig. 2b).
We performed subgroup analyses with the goal of
identifying specific subgroups of SGACC patients who
can benefit most from POCRT. To this aim, the patho-
logical parameters were separately examined in the pro-
pensity score-matched cohort (33 patient pairs). The
results indicated that SGACC patients with positive surgi-
cal margins (P = .011 and .050), PNI (P = .013 and .035), or
stage III − IV disease (P = .040 and .017) had significantly
higher 5- and 8 year LRC and ORPFS rates when treated
with POCRT, respectively (Table 3, Fig. 3). However, again
we did not find significant differences between the PORT
and POCRT groups in terms of DMFS, DFS, and OS fol-
lowing stratification for these parameters. Subgroup ana-
lyses of patients with ECS, skin invasion, and invasion to
the lymphatics or vascular space were not meaningful be-
cause of small sample sizes.
Treatment-related complications
Acute grade 0–2 and grade 3 mucositis occurred in
68 and 32 % of patients in the PORT group, respect-
ively, as compared with 64 and 36 % in the POCRT
arm (P = .778). Grade 0–2 and grade 3 dermatitis were
observed in 94 and 6 % of patients in the PORT group, re-
spectively, as compared with 92 and 8 % in the POCRT
arm (P = .859). In the POCRT group, grade 0–2 and grade
Table 2 Baseline characteristics of the 11 patients with salivary gland adenoid cystic carcinoma who developed locoregional
recurrences after adjuvant therapy
Case Tumor location pT pN Stage M ECS PNI BI SI MI LI VI LR RR DM Arm
1 Parotid gland 4 0 IVa + - + - - + - - + (in-field) - + PORT
2 Parotid gland 2 0 II + - + - - - - - + (in-field) + (in-field) + PORT
3 Hard palate 4 1 IVa + + + + - + - - + (in-field) - + POCRT
4 Hard palate 4 0 IVa + - + + - + - - + (in-field) - + PORT
5 Nasal cavity 4 0 IVa + - + + - + - - + (in-field) - + PORT
6 Gingivae 4 0 IVa + - + + - - - + + (in-field) - + PORT
7 Submandibular gland 1 2b IVa + - + - - + - - + (in-field) + (in- & out-field) - PORT
8 Submandibular gland 4 0 IVa + - + - - + - - - + (in-field) + PORT
9 Submandibular gland 2 0 II + - + - - - - - - + (out-field) + PORT
10 Submandibular gland 3 1 III + - + - - + + - - + (out-field) + PORT
11 Submandibular gland 4 0 IVa + - + - - + - - - + (out-field) + PORT
Abbreviations: pT pathological T stage, pN pathology N stage, M surgical margins, PNI perineural invasion, BI bone invasion, SI skin invasion, MI muscle invasion,
LI lymphatic invasion, VI vascular invasion, LR local recurrence, RR regional node recurrence, DM distant metastases, PORT postoperative radiotherapy, POCRT
postoperative chemoradiotherapy
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Fig. 1 Locoregional control, distant metastases-free survival, disease-free survival, and overall survival rates in patients with salivary gland adenoid
cystic carcinoma treated with postoperative chemoradiotherapy (POCRT) (solid lines) or postoperative radiotherapy (PORT) (dashed lines), before
(a) and after (b) propensity score matching
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3–4 hematological toxicities were identified in 77 and
23 % of patients, respectively. Grade 0–1 and grade 2 xer-
ostomia at 1 year of follow-up developed in 63 and 37 %
of patients in the PORT group, respectively, as compared
with 81 and 19 % in the POCRT arm (P = .433).
Discussion
Despite its generally indolent course, locoregional recur-
rence and distant metastases remain major clinical issues in
SGACC patients who bear adverse prognostic factors even
when aggressive treatment modalities are used [3–5, 13].
In patients with locally advanced HNSCC, POCRT has
been shown to confer survival benefits and has been in-
corporated into the current standards of care [6, 7].
However, the question as to whether the addition of
concurrent chemotherapy may improve outcomes in
SGACC patients undergoing PORT remains open. Ac-
cordingly, the available data on the clinical utility of
POCRT in patients with salivary gland cancers remain
scarce and controversial. In a matched case–control study
of salivary gland cancer patients who were treated either
with platinum-based POCRT (N = 12) or PORT alone
(N = 12), a significantly higher 3 year OS was observed in
the POCRT arm (83 % vs 44 %) after a short follow-up
period (median: 14.9 months for PORT and 31.6 months
for POCRT) [14]. In another retrospective study of 35 pa-
tients undergoing adjuvant IMRT either with (N = 22) or
without (N = 13) concurrent chemotherapy, no clear su-
periority for concurrent chemoradiation was observed
after a median follow-up time of 2.3 years [15]. Because
these studies included a markedly high number of differ-
ent histological subtypes with small simple sizes and short
follow-up periods, the question as to whether their
findings can be generalizable to SGACC remains open.
Because of the slowly progressive nature of SGACC, the
median time to recurrence following adjuvant treatment is
approximately 2–3 years [4, 5] making long-term follow-
up particularly important to obtain reliable data.
In this study, we described the long-term outcomes of
a multicenter series of SGACC patients treated with ei-
ther POCRT or PORT. Besides performing a central re-
view of all pathological specimens, we used propensity
score matching to minimize the potential bias associated
with a retrospective analysis. The results of our study
demonstrate that SGACC patients treated with POCRT
have significantly better LRC rates than those treated
with PORT (5- and 8 year; 97 and 97 % versus 79 and
67 %, P = .017, Fig. 1b), particularly in presence of posi-
tive resection margins, PNI, or stage III − IV disease
(Table 3). These findings indicate that concomitant
chemotherapy has the potential to produce substantial
radiosensitization of SGACC. Only a limited number of
published studies have investigated the feasibility of che-
moradiotherapy in SGACC patients, with the majority of
them having been focused on the potential usefulness of
definitive chemoradiotherapy. A case series of five non-
resected SGACC patients managed with definitive carbo-
platin and paclitaxel-based chemoradiotherapy showed
no locoregional recurrences after a median follow-up of
36 months, although one patient developed distant me-
tastases at 7 months [16]. In a retrospective study that
included 16 patients with locally advanced SGACC, the
use of definitive chemoradiotherapy (with either intra-
arterial or intravenous cisplatin or carboplatin) was asso-
ciated with a 5 year local progression-free survival rate
of 61 % after a median follow-up of 61 months [17]. In
this report, distant metastasis was the most common
pattern of treatment failure (five patients), and the 5 year
OS and progression-free survival rates were 87 and
39 %, respectively. Taken together, these data suggest
that platinum-based chemoradiation can exert a signifi-
cant local cancer killing effect in SGACC.
In accordance with the published literature [3–5, 17],
distant metastasis was the main pattern of treatment
failure and the most common cause of disease-specific
mortality in our study. Although our findings indicate
Fig. 2 Opioid-requiring pain-free survival in patients with salivary gland adenoid cystic carcinoma treated with post-operative chemoradiotherapy
(POCRT) (solid lines) or post-operative radiotherapy (PORT) (dashed lines), before (a) and after (b) propensity score matching
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that the addition of concurrent chemotherapy to PORT
significantly reduced locoregional relapses, we did not
observe a decrease of hematogenous spread among these
patients. Patients bearing multiple adverse prognostic
factors were still at high risk of distant failure even with
controlled locoregional disease. In addition, because of
the slowly progressive course of SGACC, the median sur-
vival in patients with recurrence was reported to be as long
as 2–3 years [18]. In our study cohort, the median survival
time after a diagnosis of locoregional recurrence was
29 months (range: 7–108 months). These observations po-
tentially explain the fact that the LRC benefit resulting
from POCRT did not translate into a survival advantage.
Because the goals of comprehensive cancer care are not
limited to maximize patient survival but also improve
quality of life, we believe that the significant reduction in
the rate of locoregional failure in SGACC patients should
be considered clinically significant (especially because this
type of failure is generally unsalvageable and symptom-
atic). Patients with locoregional relapses have several years
of life expectancy but are particularly prone to symptoms
that can seriously affect the overall quality of life
(e.g., intractable pain). The time to first use of opioid
analgesics is a meaningful clinical endpoint in the
field of oncology and has been validated for assessing
treatment efficacy in a number of previous prospect-
ive randomized trials [19–22]. Intriguingly, propensity
score analysis demonstrated that POCRT was signifi-
cantly associated with a higher ORPFS (5 year: 96 %
versus 82 %, P = .038, Fig. 2b). Subgroup analyses also
demonstrated ORPFS improvement in patients with
positive resection margins, PNI, or stage III − IV dis-
ease. These results suggest that an increase in LRC
rates may be paralleled by a reduced risk of cancer-
related pain (Table 3).
Despite every effort made to perform a very careful re-
view of our data and multiple statistical examinations,
there are still some unavoidable limitations inherent to
our study. They include, but are not limited to, the non-
randomized retrospective nature of the research and the
long enrollment period. The relatively small number of
events in this observational cohort and several unmeas-
ured factors (including subjective treatment decisions
and the varying surgical expertise over time) may have
biased our results. In addition, we cannot exclude an
underestimation of treatment-related side effects in pa-
tients who received concurrent chemotherapy in
addition to postoperative radiotherapy. In this regard,
several prospective randomized trials conducted in pa-
tients with head and neck malignancies have demon-
strated that adjuvant chemoradiation can increase grade
III − IV acute toxicities as compared with PORT alone
(EORTC 22931: 41 % vs 21 %, P = 0.001; RTOG 9501:
77 % vs 34 %, P < 0.001) [6, 7] with an insignificant
Table 3 Treatment outcomes of patients with salivary gland adenoid cystic carcinoma bearing adverse pathological risk factors in
the propensity score-matched cohort, treatment with PORT versus POCRT
LRC DMFS DFS OS ORPFS
Variable N 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P 5-yr 8-yr P
Stage III-IV
PORT 15 70.6 49.4 .040 47.7 47.7 .601 40.9 32.7 .963 77.8 60.0 .705 62.2 43.6 .017
POCRT 19 94.4 94.4 43.8 29.2 43.8 29.2 75.9 60.7 92.9 92.9
Margins < 1 mm
PORT 26 73.7 60.5 .011 59.0 59.0 .669 54.3 48.3 .972 86.2 74.1 .894 81.6 68.2 .050
POCRT 28 96.4 96.4 54.5 37.4 54.5 37.4 79.8 71.8 95.5 95.5
Perineural invasion
PORT 24 73.1 58.6 .013 54.5 54.5 .849 49.9 43.7 .857 81.6 69.2 .792 77.2 63.4 .035
POCRT 27 96.2 96.2 52.1 41.7 52.1 41.7 77.2 68.7 95.0 95.0
Bone invasion
PORT 8 87.5 52.5 .425 45.0 45.0 .652 45.0 30.0 .851 72.9 72.9 .220 72.9 43.8 .260
POCRT 11 90.0 90.0 50.5 50.5 50.5 50.5 52.6 52.6 83.3 83.3
Muscle invasion
PORT 11 57.3 43.0 .240 54.5 54.5 .260 43.0 28.6 .608 77.9 48.7 .772 54.5 40.9 .214
POCRT 7 85.7 85.7 19.0 19.0 19.0 19.0 80.0 80.0 83.3 83.3
Data for survival estimates are expressed as percentages
Abbreviations: PORT postoperative radiotherapy, POCRT postoperative chemoradiotherapy, LRC locoregional control, DMFS distant metastasis-free survival,
DFS disease-free survival, OS overall survival, ORPFS opioid-requiring pain-free survival
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higher incidence of grade III −V late complications
(RTOG 9501/intergroup long-term report: 24.9 % vs
20.5 %, P = 0.34) [23]. We are also aware that a median
follow-up of 71 months is relatively short for the
assessment of survival outcomes in patients with a
slowly progressive malignancy like SGACC. However,
its low prevalence makes prospective treatment trials
difficult to conduct. The ongoing RTOG 1008 ran-
domized trial has been designed to investigate the ef-
ficacy of cisplatin-based POCRT in patients with
salivary gland carcinomas and a pathologic stage of
T3-4, N1-3, or surgical margins ≤ 1 mm. However,
this trial aims to enroll patients with a wide range of
histological subtypes (including adenocarcinoma,
mucoepidermoid carcinoma, salivary duct carcinoma,
acinic cell carcinoma, and SGACC) until a sample
size of 120 cases is achieved. Although the results of
this trial will be paramount for clarifying the feasibil-
ity of POCRT in patients with salivary gland carcin-
omas, it is unclear whether the findings will be
generalizable to SGACC. We therefore believe that
our multicenter study using propensity score match-
ing may add valuable information on the clinical use-
fulness of adding concurrent chemotherapy to PORT
for SGACC patients.
Conclusions
The results from our study indicate that the addition of
concurrent chemotherapy to PORT may increase LRC
and ORPFS rates in SGACC patients, particularly in
presence of stage III − IV disease, positive surgical mar-
gins, or PNI. Unfortunately, no statistically significant
differences were observed in terms of DMFS, DFS, and
OS. The occurrence of distant metastases remains a
major clinical issue in patients bearing adverse prognos-
tic factors. Consequently, further studies on the potential
usefulness of concurrent chemotherapy and the clinical
value of novel systemic agents for SGACC are urgently
required.
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